Literature DB >> 26412600

The use of anticoagulants in morbidly obese patients.

Justyna Domienik-Karłowicz1, Piotr Pruszczyk.   

Abstract

Due to its constantly growing incidence, obesity is an increasingly serious social and medical problem. Available data on the use of novel oral anticoagulants in morbidly obese and obese patients are very limited. However, we tried to summarize the available knowledge on the use of anticoagulants in this subpopulation of patients in everyday clinical practice. Studies on the clinical use of anticoagulants provide a poor basis for any adjustment of doses in obese patients as compared to patients with normal body weight. In our opinion, further studies are required in this particular population.

Entities:  

Keywords:  anticoagulant drugs; bariatric surgery; factor Xa inhibitors; heparin; morbid obesity; obesity

Mesh:

Substances:

Year:  2015        PMID: 26412600     DOI: 10.5603/CJ.a2015.0054

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  5 in total

1.  Pulmonary embolism in a morbidly obese patient receiving dabigatran.

Authors:  Usama Nasir
Journal:  Clin Cardiol       Date:  2017-07-10       Impact factor: 2.882

2.  The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.

Authors:  Cherie Chu; Louis Lteif; Nicole Young
Journal:  Hawaii J Med Public Health       Date:  2017-06

3.  Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.

Authors:  Majdoleen Alalawneh; Ahmed Awaisu; Ousama Rachid
Journal:  Clin Pharmacokinet       Date:  2022-10-06       Impact factor: 5.577

4.  Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese.

Authors:  Kimberley Doucette; Hira Latif; Anusha Vakiti; Eshetu Tefera; Bhavisha Patel; Kelly Fitzpatrick
Journal:  Adv Hematol       Date:  2020-05-23

5.  Nutritional management of a patient with obesity and pulmonary embolism: a case report.

Authors:  Maria Luisa Fonte; Lauren Fietchner; Matteo Manuelli; Hellas Cena
Journal:  Nutr J       Date:  2016-10-19       Impact factor: 3.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.